For PDAC, Yuzawa et al. have provided the clinical evidence that patients who are strongly PDGFRβ positive on the tumor stroma are significantly worse off in terms of lymphatic invasion, lymph node metastasis and median OS (22.5 months for lower PDGFRβ vs. 13.0 months for higher PDGFRβ) than those with intermediate or weak positivity [39,40,41]. The gene discussed is PDGFRB; the disease is metastatic malignant neoplasm in the lymph nodes.